Filtered By:
Condition: Diabetes
Nutrition: Vitamin K
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 131 results found since Jan 2013.
Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives
AbstractAtrial fibrillation is the most common arrhythmia and its prevalence is expected to further increase. Patients with atrial fibrillation have an increased risk of stroke (fivefold increased risk), heart failure, and death. In patients with non-valvular atrial fibrillation, the most recent guidelines recommend the use of the CHA2DS2-VASc (congestive heart failure, arterial hypertension, age > 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) scoring system to identify those who may benefit from oral anticoagulant treatment. Guidelines recommen...
Source: Internal and Emergency Medicine - March 1, 2020 Category: Emergency Medicine Source Type: research
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial
ConclusionIn ENSURE-AF, thromboembolic events were rare and absolute bleeding event rates were higher with concomitant APT. These findings may be relevant for AF-patients considered for dual therapy; even for a short treatment duration of 1 month.
Source: Clinical Research in Cardiology - March 30, 2020 Category: Cardiology Source Type: research
Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review
AbstractPurpose of ReviewWe investigated the risk profiles of patients using direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to estimate the importance of potential (measured or unmeasured) confounding factors in analyses comparing these drugs. We searched MEDLINE and EMBASE (2008 –2018) for relevant studies and extracted information on age, sex, comorbidity, Charlson comorbidity index, HAS-BLED score (assessing risk of bleeding) and CHA2DS2-VASc score (assessing risk of stroke).Recent FindingsOverall, 66 studies with 2,808,757 patients were included. Most patients were from Fr...
Source: Current Epidemiology Reports - November 14, 2020 Category: Epidemiology Source Type: research
Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.
CONCLUSION: Oral anticoagulation therapy with NOACs was found to be more effective than warfarin therapy among older adults with NVAF and comorbid DM.
PMID: 33327796 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Clinical Outcome in Patients With Intracerebral Hemorrhage Stratified by Type of Antithrombotic Therapy
Conclusions: Patients with antithrombotic therapy have worse clinical outcome after ICH. Patients using VKA have higher risk of poor outcome and mortality compared to patients using AP. These findings highlight the deleterious effect of antithrombotic therapy in patients with ICH and stress the need for effective therapies for ICH patients.
Source: Frontiers in Neurology - June 7, 2021 Category: Neurology Source Type: research
Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis
AbstractOral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF). We sought to determine predictors of OAC initiation in AF patients presenting to the emergency department (ED). Secondary analysis of the RE-LY AF registry which enrolled individuals from 47 countries between 2007 and 2011 who presented to an ED with AF and followed them for 1 year. A total of 4149 patients with AF as their primary diagnosis who were not already taking OAC and had a CHA2DS2-VASc ≥ 1 for men or ≥ 2 for women were included in this analysis. Of these individuals, 26.8% were started on OAC (99.2% vi...
Source: Journal of Thrombosis and Thrombolysis - August 2, 2021 Category: Hematology Source Type: research
Direct Oral Anticoagulants in Cardiac Amyloidosis –Associated Heart Failure and Atrial Fibrillation
Atrial fibrillation (AF) is present in approximately 40% of patients with cardiac amyloidosis.1 AF in the setting of cardiac amyloidosis is associated with a significant risk of stroke and systemic thromboembolism regardless of the patient's CHA ₂DS₂-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score.2 Although current guidelines recommend anticoagulation therapy in all patients with cardiac amyloidosis and AF, data about the comparative effectiveness and safety of vitamin K antagonists (VKAs) ...
Source: The American Journal of Cardiology - November 27, 2021 Category: Cardiology Authors: Amgad Mentias, Paulino Alvarez, Pulkit Chaudhury, Michael Nakhla, Rohit Moudgil, Mohamad Kanj, Mazen Hanna, Milind Y. Desai Source Type: research
Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists
Conclusion
In our cohort of AF patients, Med-Diet is not associated with changes in TTR, and thus can be recommended for AF patients who are taking VKAs.
Source: Europace - August 13, 2015 Category: Cardiology Authors: Pignatelli, P., Pastori, D., Vicario, T., Bucci, T., Del Ben, M., Russo, R., Tanzilli, A., Nardoni, M. L., Bartimoccia, S., Nocella, C., Ferro, D., Saliola, M., Cangemi, R., Lip, G. Y. H., Violi, F. Tags: Atrial fibrillation Source Type: research
Vitamin K antagonists with or without long ‐term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events
ConclusionsIn this observational analysis, the use of APT in addition to OAC in patients with stable CAD and AF was not associated with lower risk of ischemic events but possibly with higher bleeding rates. Randomized trials are necessary to determine the optimal long‐term antithrombotic strategy.
Source: Clinical Cardiology - July 10, 2017 Category: Cardiology Authors: Gilles Lemesle, Gregory Ducrocq, Yedid Elbez, Eric Van Belle, Shinya Goto, Christopher P. Cannon, Christophe Bauters, Deepak L. Bhatt, Philippe Gabriel Steg, Tags: CLINICAL INVESTIGATIONS Source Type: research
Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in Internal Medicine and Neurology departments of Spain.
CONCLUSIONS: Although there were some differences in the clinical profile of patients with atrial fibrillation attended in Neurology or Internal Medicine departments, all of them had many comorbidities and a high thromboembolic risk. Despite INR control was poor, the most common oral anticoagulant used were vitamin K antagonists. Satisfaction related to oral anticoagulation was high.
PMID: 28990646 [PubMed - in process]
Source: Revista de Neurologia - October 12, 2017 Category: Neurology Tags: Rev Neurol Source Type: research
Use of non ‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
ConclusionsThe efficacy and safety of non‐vitamin K oral anticoagulants compared with warfarin generally extend to participants with diabetes mellitus, although dedicated randomized trials or real‐world data are lacking.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - February 13, 2018 Category: Endocrinology Authors: O. Itzhaki, B. Zadok, A. Eisen Tags: Review Source Type: research
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation
ConclusionIn a contemporary setting among VKA-experienced NVAF patients; VKA is still prevalent although about 30% by December 2015 had shifted to a NOAC.
Source: Europace - June 28, 2017 Category: Cardiology Source Type: research
Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria.
CONCLUSIONS: Atrial fibrillation was highly prevalent among our study population. Reduced and mid-range left ventricular ejection fraction, valvular heart disease, and HTN were the risk factors with the strongest association with AF. Although a large number of our AF patients were administered antithrombotic treatment, the prescription rate of oral anticoagulants should be further improved.
PMID: 30344265 [PubMed - in process]
Source: Medicina (Kaunas) - May 25, 2018 Category: Universities & Medical Training Authors: Naydenov S, Runev N, Manov E, Vasileva D, Rangelov Y, Naydenova N Tags: Medicina (Kaunas) Source Type: research
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
Conclusions: Nonpersistence was significantly lower with NOAC than VKA in both the maintenance and new-starter groups. In only the new-starter group, apixaban or edoxaban showed higher persistence rates than rivaroxaban.
PMID: 31014064 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - April 24, 2019 Category: Internal Medicine Authors: Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Park HW, Choi EK, Kim JB, Kim C, Kim J, Joung B Tags: Korean J Intern Med Source Type: research
Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.
CONCLUSIONS: Despite OAC, patients with concomitant AF and CKD remain at high risk for LAA thrombus formation.
PMID: 32207840 [PubMed - as supplied by publisher]
Source: Cardiology Journal - March 23, 2020 Category: Cardiology Authors: Budnik M, Gawałko M, Gorczyca I, Uziębło-Życzkowska B, Krzesińki P, Kochanowski J, Scisło P, Michalska A, Jelonek O, Starzyk K, Jurek A, Kiliszek M, Wożakowska-Kapłon B, Gielerak G, Filipiak KJ, Opolski G, Kapłon-Cieślicka A Tags: Cardiol J Source Type: research
